^
MSI-H/dMMR
|
Endometrial Cancer
|
MSI-H/dMMR
|
Endometrial Cancer
|
pembrolizumab Sensitive: A1 - Approval
Merck (MSD) Press Release - 3 weeks (NewA1)
|
pembrolizumab Sensitive: A1 - Approval
Merck (MSD) Press Release - 3 weeks - (New A1)
|
ARID1A mutation
|
Endometrial Cancer
|
ARID1A mutation
|
Endometrial Cancer
|
bevacizumab + rucaparib Sensitive: C3 – Early Trials
Gynecol Oncol - 3 weeks (NewC3)
|
bevacizumab + rucaparib Sensitive: C3 – Early Trials
Gynecol Oncol - 3 weeks - (New C3)
|
No biomarker
|
Endometrial Cancer
|
No biomarker
|
Endometrial Cancer
|
pembrolizumab + lenvatinib Sensitive: A1 - Approval
|
pembrolizumab + lenvatinib Sensitive: A1 - Approval
|
MSI-H/dMMR
|
Endometrial Cancer
|
MSI-H/dMMR
|
Endometrial Cancer
|
dostarlimab Sensitive: A1 - Approval
|
dostarlimab Sensitive: A1 - Approval
|
MSI-H/dMMR
|
Endometrial Cancer
|
MSI-H/dMMR
|
Endometrial Cancer
|
pembrolizumab + lenvatinib Sensitive: A2 - Guideline
|
pembrolizumab + lenvatinib Sensitive: A2 - Guideline
|
HER-2 expression
|
Endometrial Adenocarcinoma
|
HER-2 expression
|
Endometrial Adenocarcinoma
|
trastuzumab Sensitive: A2 - Guideline
|
trastuzumab Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Endometrial Cancer
|
NTRK1 fusion
|
Endometrial Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Endometrial Cancer
|
NTRK2 fusion
|
Endometrial Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Endometrial Cancer
|
NTRK3 fusion
|
Endometrial Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
No biomarker
|
Endometrial Cancer
|
No biomarker
|
Endometrial Cancer
|
cisplatin + paclitaxel + SGN-15 Sensitive: A2 - Guideline
|
cisplatin + paclitaxel + SGN-15 Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Endometrial Cancer
|
NTRK1 fusion
|
Endometrial Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
No biomarker
|
Endometrial Cancer
|
No biomarker
|
Endometrial Cancer
|
carboplatin + docetaxel Sensitive: A2 - Guideline
|
carboplatin + docetaxel Sensitive: A2 - Guideline
|
No biomarker
|
Endometrial Cancer
|
No biomarker
|
Endometrial Cancer
|
docetaxel Sensitive: A2 - Guideline
|
docetaxel Sensitive: A2 - Guideline
|
HER-2 positive
|
Endometrial Cancer
|
HER-2 positive
|
Endometrial Cancer
|
trastuzumab Sensitive: A2 - Guideline
|
trastuzumab Sensitive: A2 - Guideline
|
TMB-H
|
Endometrial Cancer
|
TMB-H
|
Endometrial Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Endometrial Cancer
|
No biomarker
|
Endometrial Cancer
|
cisplatin + ifosfamide Sensitive: A2 - Guideline
|
cisplatin + ifosfamide Sensitive: A2 - Guideline
|
No biomarker
|
Endometrial Cancer
|
No biomarker
|
Endometrial Cancer
|
paclitaxel + ifosfamide Sensitive: A2 - Guideline
|
paclitaxel + ifosfamide Sensitive: A2 - Guideline
|
No biomarker
|
Endometrial Cancer
|
No biomarker
|
Endometrial Cancer
|
ifosfamide Sensitive: A2 - Guideline
|
ifosfamide Sensitive: A2 - Guideline
|
No biomarker
|
Endometrial Cancer
|
No biomarker
|
Endometrial Cancer
|
topotecan Sensitive: A2 - Guideline
|
topotecan Sensitive: A2 - Guideline
|
No biomarker
|
Endometrial Cancer
|
No biomarker
|
Endometrial Cancer
|
albumin-bound paclitaxel Sensitive: A2 - Guideline
|
albumin-bound paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Endometrial Cancer
|
No biomarker
|
Endometrial Cancer
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Endometrial Cancer
|
No biomarker
|
Endometrial Cancer
|
cisplatin + SGN-15 Sensitive: A2 - Guideline
|
cisplatin + SGN-15 Sensitive: A2 - Guideline
|
No biomarker
|
Endometrial Cancer
|
No biomarker
|
Endometrial Cancer
|
pegylated liposomal doxorubicin Sensitive: A2 - Guideline
|
pegylated liposomal doxorubicin Sensitive: A2 - Guideline
|
No biomarker
|
Endometrial Cancer
|
No biomarker
|
Endometrial Cancer
|
SGN-15 Sensitive: A2 - Guideline
|
SGN-15 Sensitive: A2 - Guideline
|
No biomarker
|
Endometrial Cancer
|
No biomarker
|
Endometrial Cancer
|
carboplatin Sensitive: A2 - Guideline
|
carboplatin Sensitive: A2 - Guideline
|
No biomarker
|
Endometrial Cancer
|
No biomarker
|
Endometrial Cancer
|
cisplatin Sensitive: A2 - Guideline
|
cisplatin Sensitive: A2 - Guideline
|
No biomarker
|
Endometrial Cancer
|
No biomarker
|
Endometrial Cancer
|
carboplatin + paclitaxel Sensitive: A2 - Guideline
|
carboplatin + paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Endometrial Cancer
|
No biomarker
|
Endometrial Cancer
|
temsirolimus Sensitive: A2 - Guideline
|
temsirolimus Sensitive: A2 - Guideline
|
No biomarker
|
Endometrial Cancer
|
No biomarker
|
Endometrial Cancer
|
bevacizumab Sensitive: A2 - Guideline
|
bevacizumab Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Endometrial Cancer
|
NTRK3 fusion
|
Endometrial Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Endometrial Cancer
|
NTRK2 fusion
|
Endometrial Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
No biomarker
|
Endometrial Cancer
|
No biomarker
|
Endometrial Cancer
|
tamoxifen + medroxyprogesterone Sensitive: A2 - Guideline
|
tamoxifen + medroxyprogesterone Sensitive: A2 - Guideline
|
No biomarker
|
Endometrial Cancer
|
No biomarker
|
Endometrial Cancer
|
tamoxifen Sensitive: A2 - Guideline
|
tamoxifen Sensitive: A2 - Guideline
|
No biomarker
|
Endometrial Cancer
|
No biomarker
|
Endometrial Cancer
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
No biomarker
|
Endometrial Cancer
|
No biomarker
|
Endometrial Cancer
|
fulvestrant Sensitive: A2 - Guideline
|
fulvestrant Sensitive: A2 - Guideline
|
No biomarker
|
Endometrial Cancer
|
No biomarker
|
Endometrial Cancer
|
Aromatase inhibitor Sensitive: A2 - Guideline
|
Aromatase inhibitor Sensitive: A2 - Guideline
|
No biomarker
|
Endometrial Cancer
|
No biomarker
|
Endometrial Cancer
|
medroxyprogesterone Sensitive: A2 - Guideline
|
medroxyprogesterone Sensitive: A2 - Guideline
|
No biomarker
|
Endometrial Cancer
|
No biomarker
|
Endometrial Cancer
|
megestrol Sensitive: A2 - Guideline
|
megestrol Sensitive: A2 - Guideline
|
No biomarker
|
Endometrial Cancer
|
No biomarker
|
Endometrial Cancer
|
tamoxifen + megestrol Sensitive: A2 - Guideline
|
tamoxifen + megestrol Sensitive: A2 - Guideline
|
No biomarker
|
Endometrial Cancer
|
No biomarker
|
Endometrial Cancer
|
everolimus + letrozole Sensitive: A2 - Guideline
|
everolimus + letrozole Sensitive: A2 - Guideline
|
CTNNB1 mutation
|
Endometrial Cancer
|
CTNNB1 mutation
|
Endometrial Cancer
|
PRI724 + SM04690 Sensitive: B - Late Trials
|
PRI724 + SM04690 Sensitive: B - Late Trials
|
CTNNB1 mutation
|
Endometrial Cancer
|
CTNNB1 mutation
|
Endometrial Cancer
|
SM04690 Sensitive: B - Late Trials
|
SM04690 Sensitive: B - Late Trials
|
No biomarker
|
Endometrial Adenocarcinoma
|
No biomarker
|
Endometrial Adenocarcinoma
|
ZN-c3 Sensitive: B - Late Trials
|
ZN-c3 Sensitive: B - Late Trials
|
HER-2 overexpression
|
Endometrial Adenocarcinoma
|
HER-2 overexpression
|
Endometrial Adenocarcinoma
|
trastuzumab Sensitive: C1 - Off-label
|
trastuzumab Sensitive: C1 - Off-label
|
HER-2 positive
|
Endometrial Adenocarcinoma
|
HER-2 positive
|
Endometrial Adenocarcinoma
|
trastuzumab Sensitive: C1 - Off-label
|
trastuzumab Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Endometrial Cancer
|
BRCA1 mutation
|
Endometrial Cancer
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
BRCA2 mutation
|
Endometrial Cancer
|
BRCA2 mutation
|
Endometrial Cancer
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
KRAS G12C
|
Endometrial Cancer
|
KRAS G12C
|
Endometrial Cancer
|
sotorasib Sensitive: C1 - Off-label
|
sotorasib Sensitive: C1 - Off-label
|
KIT expression
|
Endometrial Cancer
|
KIT expression
|
Endometrial Cancer
|
imatinib Sensitive: C1 - Off-label
|
imatinib Sensitive: C1 - Off-label
|
HER-2 overexpression
|
Endometrial Cancer
|
HER-2 overexpression
|
Endometrial Cancer
|
trastuzumab Sensitive: C1 - Off-label
|
trastuzumab Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Endometrial Cancer
|
BRCA1 mutation
|
Endometrial Cancer
|
niraparib Sensitive: C1 - Off-label
|
niraparib Sensitive: C1 - Off-label
|
MSI-H/dMMR
|
Endometrial Cancer
|
MSI-H/dMMR
|
Endometrial Cancer
|
retifanlimab Sensitive: C2 – Inclusion Criteria
|
retifanlimab Sensitive: C2 – Inclusion Criteria
|
ER positive
|
Endometrial Cancer
|
ER positive
|
Endometrial Cancer
|
ribociclib + letrozole Sensitive: C2 – Inclusion Criteria
|
ribociclib + letrozole Sensitive: C2 – Inclusion Criteria
|
POLE mutation
|
Endometrial Cancer
|
POLE mutation
|
Endometrial Cancer
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
FGFR2 S252W
|
Endometrial Cancer
|
FGFR2 S252W
|
Endometrial Cancer
|
ponatinib Sensitive: C2 – Inclusion Criteria
|
ponatinib Sensitive: C2 – Inclusion Criteria
|
MSI-H/dMMR
|
Endometrial Cancer
|
MSI-H/dMMR
|
Endometrial Cancer
|
avelumab Sensitive: C2 – Inclusion Criteria
|
avelumab Sensitive: C2 – Inclusion Criteria
|
POLE mutation
|
Endometrial Cancer
|
POLE mutation
|
Endometrial Cancer
|
avelumab Sensitive: C2 – Inclusion Criteria
|
avelumab Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
|
Endometrial Cancer
|
HER-2 amplification
|
Endometrial Cancer
|
ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria
|
ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria
|
MSI-H/dMMR
|
Endometrial Adenocarcinoma
|
MSI-H/dMMR
|
Endometrial Adenocarcinoma
|
AZD1775 Sensitive: C3 – Early Trials
|
AZD1775 Sensitive: C3 – Early Trials
|
HER-2 positive
|
Endometrial Adenocarcinoma
|
HER-2 positive
|
Endometrial Adenocarcinoma
|
trastuzumab Sensitive: C3 – Early Trials
|
trastuzumab Sensitive: C3 – Early Trials
|
ER positive
|
Endometrial Cancer
|
ER positive
|
Endometrial Cancer
|
palbociclib + letrozole Sensitive: C3 – Early Trials
|
palbociclib + letrozole Sensitive: C3 – Early Trials
|
DKK1 overexpression
|
Endometrial Cancer
|
DKK1 overexpression
|
Endometrial Cancer
|
DKN-01 Sensitive: C3 – Early Trials
|
DKN-01 Sensitive: C3 – Early Trials
|
MCL1 amplification
|
Endometrial Cancer
|
MCL1 amplification
|
Endometrial Cancer
|
CYC065 Sensitive: C3 – Early Trials
|
CYC065 Sensitive: C3 – Early Trials
|
KRAS G12C
|
Endometrial Cancer
|
KRAS G12C
|
Endometrial Cancer
|
MRTX849 Sensitive: C3 – Early Trials
|
MRTX849 Sensitive: C3 – Early Trials
|
ATM PI2629fs*
|
Endometrial Cancer
|
ATM PI2629fs*
|
Endometrial Cancer
|
BAY 1895344 Sensitive: C3 – Early Trials
|
BAY 1895344 Sensitive: C3 – Early Trials
|
FOLR1 expression
|
Endometrial Cancer
|
FOLR1 expression
|
Endometrial Cancer
|
IMGN 853 Sensitive: C3 – Early Trials
|
IMGN 853 Sensitive: C3 – Early Trials
|
PD-L1 expression
|
Endometrial Cancer
|
PD-L1 expression
|
Endometrial Cancer
|
AB122 Sensitive: C3 – Early Trials
|
AB122 Sensitive: C3 – Early Trials
|
TMB-H
|
Endometrial Cancer
|
TMB-H
|
Endometrial Cancer
|
AB122 Sensitive: C3 – Early Trials
|
AB122 Sensitive: C3 – Early Trials
|
POLE V411L
|
Endometrial Cancer
|
POLE V411L
|
Endometrial Cancer
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
POLE P286R
|
Endometrial Cancer
|
POLE P286R
|
Endometrial Cancer
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
PTEN mutation
|
Endometrial Cancer
|
PTEN mutation
|
Endometrial Cancer
|
LY3023414 Sensitive: C3 – Early Trials
|
LY3023414 Sensitive: C3 – Early Trials
|
PIK3R1 mutation
|
Endometrial Cancer
|
PIK3R1 mutation
|
Endometrial Cancer
|
LY3023414 Sensitive: C3 – Early Trials
|
LY3023414 Sensitive: C3 – Early Trials
|
BRCA1 mutation
|
Endometrial Cancer
|
BRCA1 mutation
|
Endometrial Cancer
|
rucaparib + sacituzumab govitecan-hziy Sensitive: C3 – Early Trials
|
rucaparib + sacituzumab govitecan-hziy Sensitive: C3 – Early Trials
|
KRAS mutation
|
Endometrial Cancer
|
KRAS mutation
|
Endometrial Cancer
|
VS-6766 Sensitive: C3 – Early Trials
|
VS-6766 Sensitive: C3 – Early Trials
|
PTEN-L
|
Endometrial Cancer
|
PTEN-L
|
Endometrial Cancer
|
cobimetinib + RG7440 Sensitive: C3 – Early Trials
|
cobimetinib + RG7440 Sensitive: C3 – Early Trials
|
KRAS mutation
|
Endometrial Cancer
|
KRAS mutation
|
Endometrial Cancer
|
cobimetinib + RG7440 Sensitive: C3 – Early Trials
|
cobimetinib + RG7440 Sensitive: C3 – Early Trials
|
HER-2 expression
|
Endometrial Cancer
|
HER-2 expression
|
Endometrial Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials
|
fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials
|
AKT1 mutation
|
Endometrial Cancer
|
AKT1 mutation
|
Endometrial Cancer
|
temsirolimus Sensitive: C3 – Early Trials
|
temsirolimus Sensitive: C3 – Early Trials
|
CTNNB1 mutation
|
Endometrial Cancer
|
CTNNB1 mutation
|
Endometrial Cancer
|
everolimus + letrozole Sensitive: C3 – Early Trials
|
everolimus + letrozole Sensitive: C3 – Early Trials
|
CTNNB1 mutation
|
Endometrial Cancer
|
CTNNB1 mutation
|
Endometrial Cancer
|
temsirolimus Sensitive: C3 – Early Trials
|
temsirolimus Sensitive: C3 – Early Trials
|
EGFR E690K
|
Endometrial Cancer
|
EGFR E690K
|
Endometrial Cancer
|
lapatinib Sensitive: C3 – Early Trials
|
lapatinib Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Endometrial Cancer
|
HER-2 amplification
|
Endometrial Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials
|
fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials
|
KRAS mutation
|
Endometrial Cancer
|
KRAS mutation
|
Endometrial Cancer
|
BGB-283 Sensitive: C3 – Early Trials
|
BGB-283 Sensitive: C3 – Early Trials
|
PTEN deletion
|
Endometrial Cancer
|
PTEN deletion
|
Endometrial Cancer
|
olaparib Sensitive: C3 – Early Trials
|
olaparib Sensitive: C3 – Early Trials
|
TSC1 mutation
|
Endometrial Cancer
|
TSC1 mutation
|
Endometrial Cancer
|
temsirolimus Sensitive: C3 – Early Trials
|
temsirolimus Sensitive: C3 – Early Trials
|
TSC2 mutation
|
Endometrial Cancer
|
TSC2 mutation
|
Endometrial Cancer
|
temsirolimus Sensitive: C3 – Early Trials
|
temsirolimus Sensitive: C3 – Early Trials
|
FGFR2-BICC1 fusion
|
Endometrial Cancer
|
FGFR2-BICC1 fusion
|
Endometrial Cancer
|
erdafitinib Sensitive: C3 – Early Trials
|
erdafitinib Sensitive: C3 – Early Trials
|
FGFR2-OFD1 fusion
|
Endometrial Cancer
|
FGFR2-OFD1 fusion
|
Endometrial Cancer
|
erdafitinib Sensitive: C3 – Early Trials
|
erdafitinib Sensitive: C3 – Early Trials
|
LRP1B mutation
|
Endometrial Cancer
|
LRP1B mutation
|
Endometrial Cancer
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
LRP1B mutation
|
Endometrial Cancer
|
LRP1B mutation
|
Endometrial Cancer
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Endometrial Cancer
|
HER-2 amplification
|
Endometrial Cancer
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
HER-2 overexpression
|
Endometrial Cancer
|
HER-2 overexpression
|
Endometrial Cancer
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
HER-2 amplification
|
Endometrial Cancer
|
HER-2 amplification
|
Endometrial Cancer
|
pyrotinib Sensitive: C3 – Early Trials
|
pyrotinib Sensitive: C3 – Early Trials
|
MSH2 deletion
|
Endometrial Cancer
|
MSH2 deletion
|
Endometrial Cancer
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
